Amphastar Pharmaceuticals, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $74.3M | $479.5M | $172.6M |
| Jun 2022 | $73.9M | $499.3M | $166.2M |
| Sep 2022 | $74.0M | $505.2M | $157.2M |
| Dec 2022 | $76.6M | $528.7M | $156.1M |
| Mar 2023 | $72.9M | $548.6M | $176.6M |
| Jun 2023 | $488.3M | $589.2M | $148.6M |
| Sep 2023 | $653.3M | $595.1M | $266.8M |
| Dec 2023 | $603.2M | $639.4M | $144.3M |
| Mar 2024 | $594.0M | $672.4M | $201.1M |
| Jun 2024 | $586.9M | $713.3M | $189.6M |
| Sep 2024 | $596.4M | $727.7M | $192.1M |
| Dec 2024 | $613.5M | $732.3M | $151.6M |
| Mar 2025 | $603.9M | $751.3M | $182.8M |
| Jun 2025 | $607.7M | $757.5M | $187.7M |
| Sep 2025 | $608.6M | $776.7M | $216.3M |
| Dec 2025 | $619.7M | $788.8M | $170.2M |
| Mar 2026 | $609.8M | $773.4M | $170.9M |
| Jun 2026 | $609.6M | $768.2M | $223.6M |